Crosstalk between TF/FVIIa and EGFR signaling in colorectal cancer cells

References

• Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526(7572):263–267. doi:10.1038/nature14969.
   PubMed Web of Science ®Google Scholar
• Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol. 2014;8(6):1084–1094. doi:10.1016/j.molonc.2014.05.003.
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–354. doi:10.1038/nrc1609.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–1417. doi:10.1056/NEJMoa0805019.
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One. 2009;4(10):e7287. doi:10.1371/journal.pone.0007287.
   PubMed Web of Science ®Google Scholar
• Perkins G, Pilati C, Blons H, Laurent-Puig P. Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. Pharmacogenomics. 2014;15(7):1043–1052. doi:10.2217/pgs.14.66.
   PubMed Web of Science ®Google Scholar
• Evaluation of Genomic Applications in Practice and Prevention(EGAPP) Working Group.. Recommendations from the EGAPP working group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?. Genet Med. 2013;15(7):517–527. doi:10.1038/gim.2012.184.
   PubMed Web of Science ®Google Scholar
• Jia ZC, Wan YL, Tang JQ, Dai Y, Liu Y-C, Wang X, Zhu J. Tissue factor/activated factor VIIa induces matrix metalloproteinase-7 expression through activation of c-Fos via ERK1/2 and p38 MAPK signaling pathways in human colon cancer cell. Int J Colorectal Dis. 2012;27(4):437–445. doi:10.1007/s00384-011-1351-0.
   PubMed Web of Science ®Google Scholar
• Zhou H, Shi W, Zhou B, Guo D, Wang T. Tissue factor-factor VIIa regulates interleukin-8, tissue factor and caspase-7 expression in SW620 cells through protease-activated receptor-2 activation. Mol Med Rep. 2010;3(2):269–274. doi:10.3892/mmr_00000250.
   PubMed Web of Science ®Google Scholar
• Carneiro-Lobo TC, Konig S, Machado DE, Nasciutti LE, Forni MF, Francischetti IMB, Sogayar MC, Monteiro RQ. Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J Thromb Haemost. 2009;7(11):1855–1864. doi:10.1111/j.1538-7836.2009.03553.x.
   PubMed Web of Science ®Google Scholar
• Tian M, Wan Y, Tang J, Li H, Yu G, Zhu J, Ji S, Guo H, Zhang N, Li W, et al. Depletion of tissue factor suppresses hepatic metastasis and tumor growth in colorectal cancer via the downregulation of MMPs and the induction of autophagy and apoptosis. Cancer Biol Ther. 2011;12(10):896–907. doi:10.4161/cbt.12.10.17679.
   PubMed Web of Science ®Google Scholar
• Versteeg HH. Tissue factor: old and new links with cancer biology. Semin Thromb Hemost. 2015;41(7):747–755. doi:10.1055/s-0035-1556048.
   PubMed Web of Science ®Google Scholar
• Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W. Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell. 2004;15(10):4416–4425. doi:10.1091/mbc.e03-09-0640.
   PubMed Web of Science ®Google Scholar
• Wiiger MT, Prydz H. The epidermal growth factor receptor (EGFR) and proline rich tyrosine kinase 2 (PYK2) are involved in tissue factor dependent factor VIIa signalling in HaCaT cells. Thromb Haemost. 2004;92(1):13–22. doi:10.1160/TH03-08-0549.
   PubMed Web of Science ®Google Scholar
• Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood. 2010;116(5):815–818. doi:10.1182/blood-2009-10-250639.
   PubMed Web of Science ®Google Scholar
• Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009;69(6):2540–2549. doi:10.1158/0008-5472.CAN-08-1547.
   PubMed Web of Science ®Google Scholar
• Tang JQ, Fan Q, Wan YL, Liu YC, Wang X, Wu T, Pan YS, Wu WH, Zhu J. Ectopic expression and clinical significance of tissue factor/coagulation factor VII complex in colorectal cancer. Beijing Da Xue Xue Bao Yi Xue Ban. 2009;41(5):531–536.
   PubMedGoogle Scholar
• Luo H, England CG, Shi S, Graves SA, Hernandez R, Liu B, Theuer CP, Wong HC, Nickles RJ, Cai W. Dual targeting of tissue factor and CD105 for preclinical PET imaging of pancreatic cancer. Clin Cancer Res. 2016;22(15):3821–3830. doi:10.1158/1078-0432.CCR-15-2054.
   PubMed Web of Science ®Google Scholar
• Nielsen CH, Jeppesen TE, Kristensen LK, Jensen MM, El Ali HH, Madsen J, Wiinberg B, Petersen LC, Kjaer A. PET imaging of tissue factor in pancreatic cancer using 64Cu-labeled active site-inhibited factor VII. J Nucl Med. 2016;57(7):1112–1119. doi:10.2967/jnumed.115.170266.
   PubMed Web of Science ®Google Scholar
• Shi S, Hong H, Orbay H, Graves SA, Yang Y, Ohman JD, Liu B, Nickles RJ, Wong HC, Cai W. ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment. Eur J Nucl Med Mol Imaging. 2015;42(8):1295–1303. doi:10.1007/s00259-015-3038-1.
   PubMed Web of Science ®Google Scholar
• Zhu S, Kisiel W, Lu YJ, Petersen LC, Ndungu JM, Moore TW, Parker ET, Sun A, Sarkaria JN, Snyder JP, et al. Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. J Drug Target. 2015;23(3):257–265. doi:10.3109/1061186X.2014.988217.
   PubMed Web of Science ®Google Scholar
• Sato R, Obonai T, Tsumura R, Tsumoto K, Koga Y, Yasunaga M, Matsumura Y. Preparation and characterization of anti-tissue factor single-chain variable fragment antibody for cancer diagnosis. Cancer Sci. 2014;105(12):1631–1637. doi:10.1111/cas.12557.
   PubMed Web of Science ®Google Scholar
• Hu J, Muller KA, Furnari FB, Cavenee WK, VandenBerg SR, Gonias SL. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene. 2015;34(31):4078–4088. doi:10.1038/onc.2014.336.
   PubMed Web of Science ®Google Scholar
• Cheng L, Ren W, Xie L, Li M, Liu J, Hu J, Liu B-R, Qian X-P. Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. Cancer Chemother Pharmacol. 2014;74(1):1–13. doi:10.1007/s00280-014-2489-6.
   PubMed Web of Science ®Google Scholar